{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:30:31Z","timestamp":1794137431300,"version":"4.8.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102590","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:41:08Z","timestamp":1749555668000},"page":"102590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4440","authenticated-orcid":false,"given":"Martha","family":"Grogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne T.","family":"Sweetser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Capocelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102590_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2025.102590_bib2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102590_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102590_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102590_bib5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102590_bib10","unstructured":"European Medicines Agency Summary of product characteristics: Givlaari (givosiran) 189 mg\/mL solution for injection https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/givlaari-epar-product-information_en.pdf."},{"key":"10.1016\/j.omtn.2025.102590_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0304-4165(82)90040-X","article-title":"Cellular origin of prealbumin in the rat","volume":"716","author":"Felding","year":"1982","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2025.102590_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A narrative review of the role of transthyretin in health and disease","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.omtn.2025.102590_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.omtn.2025.102590_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2025.102590_bib21","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2025.102590_bib22","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.omtn.2025.102590_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.omtn.2025.102590_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","article-title":"Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey","volume":"13","author":"Gonzalez-Moreno","year":"2024","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.omtn.2025.102590_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102590_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102590_bib27","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2025.102590_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.26515","article-title":"Burden of hereditary transthyretin amyloidosis on quality of life","volume":"60","author":"Yarlas","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2025.102590_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102590_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.omtn.2025.102590_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2025.102590_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2023.2232520","article-title":"Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study","volume":"31","author":"Ticau","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2025.102590_bib38","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2025.102590_bib39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"43","author":"Damy","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2025.102590_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102590_bib41","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib42","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102590_bib43","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102590_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2025.102590_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2025.102590_bib46","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/heartjnl-2021-319063","article-title":"Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy","volume":"108","author":"Law","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.omtn.2025.102590_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of Acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib49","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102590_bib51","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omtn.2025.102590_bib52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.omtn.2025.102590_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.omtn.2025.102590_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","article-title":"Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy","volume":"27","author":"Maia","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2025.102590_bib55","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102590_bib56","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13506129.2023.2187678","article-title":"Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis","volume":"30","author":"Sato","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2025.102590_bib57","article-title":"Nfl levels significantly decrease in response to treatment with patisiran or vutrisiran in hATTR amyloidosis with polyneuropathy","volume":"92","author":"Aldinc","year":"2022"},{"key":"10.1016\/j.omtn.2025.102590_bib58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","article-title":"Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2025.102590_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214868","article-title":"Prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment","volume":"10","author":"Oghina","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib60","series-title":"XVth International Symposium on Amyloidosis (ISA)","article-title":"Natural history of wild type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","author":"Grogan","year":"2016"},{"key":"10.1016\/j.omtn.2025.102590_bib61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.omtn.2025.102590_bib62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cardfail.2023.10.035","article-title":"Primary results from APOLLO-B open-label extension study of patisiran in patients with transthyretin cardiac amyloidosis","volume":"30","author":"Maurer","year":"2024","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.omtn.2025.102590_bib63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtn.2025.102590_bib64","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cardfail.2022.10.017","article-title":"Exploratory analyses from APOLLO-B, a Phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy","volume":"29","author":"Kale","year":"2023","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.omtn.2025.102590_bib65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2025.102590_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.omtn.2025.102590_bib67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102590_bib68","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.omtn.2025.102590_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS+7","volume":"405","author":"Dyck","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omtn.2025.102590_bib70","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","article-title":"COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score","volume":"87","author":"Sletten","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.omtn.2025.102590_bib71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.omtn.2025.102590_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13506129.2022.2118043","article-title":"Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial","volume":"30","author":"Quan","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.omtn.2025.102590_bib73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40120-024-00595-9","article-title":"Impact of baseline neuropathy severity on vutrisiran treatment response in the phase 3 HELIOS-A study","volume":"13","author":"Luigetti","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.omtn.2025.102590_bib74","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2147\/TCRM.S361706","article-title":"Practical guidance for the use of patisiran in the management of polyneuropathy in hereditary transthyretin-mediated amyloidosis","volume":"19","author":"Dixon","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.omtn.2025.102590_bib75","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102590_bib76","article-title":"siRNA specificity: RNAi mechanisms and strategies to reduce off-target effects","volume":"11","author":"Neumeier","year":"2020","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.omtn.2025.102590_bib77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtn.2025.102590_bib80","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib81","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib82","article-title":"Olpasiran trials of cardiovascular events and lipoprotein(a)","year":"2022","journal-title":"Reduction (OCEAN(a)) - Outcomes Trial"},{"key":"10.1016\/j.omtn.2025.102590_bib90","author":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2025.102590_bib91","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib97","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102590_bib98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2025.102590_bib99","author":"Dicerna Pharmaceuticals"},{"key":"10.1016\/j.omtn.2025.102590_bib103","author":"Avidity Biosciences"},{"key":"10.1016\/j.omtn.2025.102590_bib108","author":"Sylentis"},{"key":"10.1016\/j.omtn.2025.102590_bib109","author":"Sylentis"},{"key":"10.1016\/j.omtn.2025.102590_bib110","author":"Sylentis"},{"key":"10.1016\/j.omtn.2025.102590_bib111","author":"Janssen Research & Development"},{"key":"10.1016\/j.omtn.2025.102590_bib113","author":"Vir Biotechnology"},{"key":"10.1016\/j.omtn.2025.102590_bib114","author":"Vir Biotechnology"},{"key":"10.1016\/j.omtn.2025.102590_bib115","author":"Vir Biotechnology"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:40:04Z","timestamp":1777322404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001441"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102590","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102590"}}